Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Kane Biotech Inc. (OTCQB: KNBIF) announced that CEO Marc Edwards will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions and presentations from various leaders in the Biotech and Healthcare sectors. Edwards expressed excitement about sharing the company's growth story, highlighting successes in commercializing products across three markets and securing government funding. Kane Biotech specializes in technologies that prevent and remove microbial biofilms, holding a robust portfolio of intellectual property.
Kane Biotech Inc. (OTCQB: KNBIF) announced that preliminary analysis of efficacy trials for STEM Animal Health's pet oral care additive has successfully met its primary endpoint. This achievement opens the door for two milestone payments from STEM's licensing partners, contingent on positive clinical efficacy data. STEM's products utilize Kane’s patented Coactiv+™ technology aimed at combating plaque and tartar biofilm in pets. The collaboration between Kane and Animalcare Group focuses on advancing biofilm-related treatments in animals.
Kane Biotech Inc. (OTCQB:KNBIF) announced leadership changes, with Mark Nawacki becoming Chairman of the Board, while Philip Renaud transitions to Vice Chair. Renaud, the outgoing Chairman, emphasized the need for experienced leadership as the company approaches crucial advancements in Wound Care. Nawacki, with a background in pharmaceutical commercialization, expressed gratitude to Renaud and committed to guiding Kane Biotech's growth. The company specializes in technologies that combat microbial biofilms and holds 52 patents, indicating its strong research foundation.
Kane Biotech Inc. announces that Kevin Cole will be the new President and CEO of STEM Animal Health Inc., its subsidiary formed through a joint venture with Animalcare Group PLC. Cole has extensive experience in the pet care industry, previously serving as President of True Leaf Pet. His focus will be on expanding STEM's reach in the $150 billion global pet care market, intent on leveraging the company's innovative biofilm-targeting technology. Additionally, a new Board of Directors has been established to support STEM, with Kane Biotech’s CEO Marc Edwards as Chairman.